Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.

Borno HT, Lichtensztajn DY, Gomez SL, Palmer NR, Ryan CJ.

Cancer. 2018 Nov 16. doi: 10.1002/cncr.31826. [Epub ahead of print]

PMID:
30444526
2.

Symptom Cluster Science in Chronic Kidney Disease: A Literature Review.

Lockwood MB, Chung S, Puzantian H, Bronas UG, Ryan CJ, Park C, DeVon HA.

West J Nurs Res. 2018 Oct 31:193945918808766. doi: 10.1177/0193945918808766. [Epub ahead of print]

PMID:
30378466
3.

Cells Lacking the RB1 Tumor Suppressor Gene are Hyperdependent on Aurora B Kinase for Survival.

Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, Flaifel A, Novak JS, Gulati A, Buss E, Younger ST, McBrayer SK, Cowley GS, Bonal DM, Nguyen QD, Brulle-Soumare L, Taylor P, Cairo S, Ryan CJ, Pease EJ, Maratea K, Travers J, Root DE, Signoretti S, Pellman D, Ashton S, Lord CJ, Barry ST, Kaelin WG.

Cancer Discov. 2018 Oct 29. pii: CD-18-0389. doi: 10.1158/2159-8290.CD-18-0389. [Epub ahead of print]

PMID:
30373918
4.

Systems biology: old news or new stimulus for biochemistry.

Kolch W, Fey D, Ryan CJ.

Essays Biochem. 2018 Oct 26;62(4):483-486. doi: 10.1042/EBC20180002. Print 2018 Oct 26.

PMID:
30366987
5.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

6.

Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.

Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R.

Clin Genitourin Cancer. 2018 Sep 24. pii: S1558-7673(18)30629-3. doi: 10.1016/j.clgc.2018.09.013. [Epub ahead of print]

PMID:
30327180
7.

Synthetic Lethality and Cancer - Penetrance as the Major Barrier.

Ryan CJ, Bajrami I, Lord CJ.

Trends Cancer. 2018 Oct;4(10):671-683. doi: 10.1016/j.trecan.2018.08.003. Epub 2018 Sep 15. Review.

PMID:
30292351
8.

Our duty to know and understand the law.

Ryan CJ.

Australas Psychiatry. 2018 Oct;26(5):453-454. doi: 10.1177/1039856218799922. No abstract available.

PMID:
30269565
9.

Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment.

Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):363-371. doi: 10.1200/EDBK_200967. Review.

10.

Organizational Factors Associated With Technical Efficiency of Nursing Care in US Intensive Care Units.

Min A, Scott LD, Park C, Vincent C, Ryan CJ.

J Nurs Care Qual. 2018 Sep 11. doi: 10.1097/NCQ.0000000000000362. [Epub ahead of print]

PMID:
30211776
11.

Genetic Variation in the Androgen Receptor and Measures of Plasma Testosterone Levels Suggest Androgen Dysfunction in Alzheimer's Disease.

Carr JS, Bonham LW, Morgans AK, Ryan CJ, Yokoyama JS, Geier EG; Alzheimer’s Disease Neuroimaging Initiative.

Front Neurosci. 2018 Aug 7;12:529. doi: 10.3389/fnins.2018.00529. eCollection 2018.

12.

BRCAness and prostate cancer: diagnostic and therapeutic considerations.

Dhawan M, Ryan CJ.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):488-498. doi: 10.1038/s41391-018-0069-2. Epub 2018 Aug 21.

PMID:
30131605
13.

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8.

14.

Community treatment orders are (somewhat) effective: Their future in the context of rights-based mental health law.

Ryan CJ.

Aust N Z J Psychiatry. 2018 Aug 9:4867418791300. doi: 10.1177/0004867418791300. [Epub ahead of print] No abstract available.

PMID:
30091367
15.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889.

16.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Erratum in: Sci Rep. 2018 Aug 21;8(1):12771.

17.

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ.

J Clin Oncol. 2018 Aug 20;36(24):2492-2503. doi: 10.1200/JCO.2017.77.6880. Epub 2018 Jul 9.

18.

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.

Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, Dittamore R, Schreiber NA, Summa JM, Youssoufian H, Morris MJ, Scher HI.

JAMA Oncol. 2018 Oct 1;4(10):1344-1351. doi: 10.1001/jamaoncol.2018.2168.

PMID:
29978216
19.

Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.

Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E, Pettitt SJ, Ryan CJ, Lord CJ.

Oncogene. 2018 Jun 18. doi: 10.1038/s41388-018-0368-z. [Epub ahead of print]

20.

Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways.

Kornberg Z, Chou J, Feng FY, Ryan CJ.

Ann Transl Med. 2018 May;6(9):161. doi: 10.21037/atm.2018.05.06. Review.

21.

Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.

Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L, Plymate SR, Praet SFE, Guinan EM, Van Blarigan EL, Casey O, Buzza M, Gledhill S, Zhang L, Galvão DA, Ryan CJ, Saad F.

BMJ Open. 2018 May 14;8(5):e022899. doi: 10.1136/bmjopen-2018-022899.

22.

At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials.

Borno HT, Zhang L, Siegel A, Chang E, Ryan CJ.

Oncologist. 2018 Oct;23(10):1242-1249. doi: 10.1634/theoncologist.2017-0628. Epub 2018 Apr 26.

PMID:
29700209
23.

Impact of Medicare Advantage penetration and hospital competition on technical efficiency of nursing care in US intensive care units.

Min A, Scott LD, Park C, Vincent C, Ryan CJ, Lee T.

Int J Health Plann Manage. 2018 Apr 10. doi: 10.1002/hpm.2528. [Epub ahead of print]

PMID:
29635856
24.

The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.

Ryan CJ, Crawford ED, Shore ND, Underwood W 3rd, Taplin ME, Londhe A, Francis PSJ, Phillips J, McGowan T, Kantoff PW.

J Urol. 2018 Aug;200(2):344-352. doi: 10.1016/j.juro.2018.03.125. Epub 2018 Apr 6.

PMID:
29630978
25.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.

Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603.

PMID:
29610289
26.

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.

Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ.

Oncologist. 2018 Jun;23(6):656-e64. doi: 10.1634/theoncologist.2017-0624. Epub 2018 Feb 27.

27.

Community treatment orders: towards a new research agenda.

Brophy L, Edan V, Gooding P, McSherry B, Burkett T, Carey S, Carroll A, Callaghan S, Finch A, Hansford M, Hanson S, Kisely S, Lawn S, Light E, Maher S, Patel G, Ryan CJ, Saltmarsh K, Stratford A, Tellez JJ, Toko M, Weller P.

Australas Psychiatry. 2018 Jun;26(3):299-302. doi: 10.1177/1039856218758543. Epub 2018 Feb 20.

PMID:
29463100
28.

Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.

Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, Small EJ, Fong L.

Clin Genitourin Cancer. 2018 Jun;16(3):184-190.e2. doi: 10.1016/j.clgc.2017.12.004. Epub 2017 Dec 27.

PMID:
29352713
29.

Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line Panels.

Campbell J, Ryan CJ, Lord CJ.

Methods Mol Biol. 2018;1711:83-99. doi: 10.1007/978-1-4939-7493-1_5.

PMID:
29344886
30.

HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.

Almassi N, Reichard C, Li J, Russell C, Perry J, Ryan CJ, Friedlander T, Sharifi N.

JAMA Oncol. 2018 Apr 1;4(4):554-557. doi: 10.1001/jamaoncol.2017.3159.

31.

Can we usefully stratify patients according to suicide risk?

Large MM, Ryan CJ, Carter G, Kapur N.

BMJ. 2017 Oct 17;359:j4627. doi: 10.1136/bmj.j4627. No abstract available.

PMID:
29042363
32.

A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events.

Ryan CJ, Kennedy S, Bajrami I, Matallanas D, Lord CJ.

Cell Syst. 2017 Oct 25;5(4):399-409.e5. doi: 10.1016/j.cels.2017.09.011. Epub 2017 Oct 11.

33.

Suicide risk assessment among psychiatric inpatients: a systematic review and meta-analysis of high-risk categories.

Large M, Myles N, Myles H, Corderoy A, Weiser M, Davidson M, Ryan CJ.

Psychol Med. 2018 May;48(7):1119-1127. doi: 10.1017/S0033291717002537. Epub 2017 Sep 6.

PMID:
28874218
34.

Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone.

Ryan CJ, Kheoh T, Li J, Molina A, De Porre P, Carles J, Efstathiou E, Kantoff PW, Mulders PFA, Saad F, Chi KN.

Clin Genitourin Cancer. 2017 Jul 25. pii: S1558-7673(17)30211-2. doi: 10.1016/j.clgc.2017.07.014. [Epub ahead of print]

PMID:
28844792
35.

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.

Pezaro CJ, Omlin A, Mastris K; ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S.

Ann Oncol. 2017 Aug 1;28(8):1692-1694. doi: 10.1093/annonc/mdx312. No abstract available.

PMID:
28838209
36.

Treatment strategies in low-volume metastatic castration-resistant prostate cancer.

Wei XX, Ko EC, Ryan CJ.

Curr Opin Urol. 2017 Nov;27(6):596-603. doi: 10.1097/MOU.0000000000000436. Review.

PMID:
28786849
37.

Authors' reply.

Ryan CJ, Newton-Howes G.

Br J Psychiatry. 2017 Aug;211(2):119-120. doi: 10.1192/bjp.211.2.119. No abstract available.

PMID:
28765314
38.

An alternative aide-mémoire to assist in the clinical assessment of suicidal patients: comment on Alyami et al.

Large M, Myles H, Ryan CJ.

Australas Psychiatry. 2017 Aug;25(4):414-415. doi: 10.1177/1039856217695708. No abstract available.

PMID:
28747108
39.

Genetic Interaction Score (S-Score) Calculation, Clustering, and Visualization of Genetic Interaction Profiles for Yeast.

Roguev A, Ryan CJ, Xu J, Colson I, Hartsuiker E, Krogan N.

Cold Spring Harb Protoc. 2018 Feb 1;2018(2):pdb.prot091983. doi: 10.1101/pdb.prot091983.

PMID:
28733406
40.

High-Throughput Quantitative Genetic Interaction Mapping in the Fission Yeast Schizosaccharomyces pombe.

Roguev A, Ryan CJ, Hartsuiker E, Krogan NJ.

Cold Spring Harb Protoc. 2018 Feb 1;2018(2):pdb.top079905. doi: 10.1101/pdb.top079905.

PMID:
28733404
41.

A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.

Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY.

Eur Urol. 2018 Feb;73(2):156-165. doi: 10.1016/j.eururo.2017.06.027. Epub 2017 Jul 14. Review.

PMID:
28716370
42.

CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer.

Bridgett S, Campbell J, Lord CJ, Ryan CJ.

Cell Syst. 2017 Jul 26;5(1):82-86.e3. doi: 10.1016/j.cels.2017.06.002. Epub 2017 Jul 12.

43.

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.

Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ.

Clin Genitourin Cancer. 2017 Dec;15(6):733-741.e1. doi: 10.1016/j.clgc.2017.05.026. Epub 2017 Jun 3.

PMID:
28655452
44.

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.

Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, Alumkal JJ, Hauke R, Tutrone RF, Saleh M, Chow Maneval E, Thomas S, Ricci DS, Yu MK, de Boer CJ, Trinh A, Kheoh T, Bandekar R, Scher HI, Antonarakis ES.

Ann Oncol. 2017 Sep 1;28(9):2264-2271. doi: 10.1093/annonc/mdx283.

45.

Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.

Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ.

Mol Cancer Res. 2017 Sep;15(9):1221-1229. doi: 10.1158/1541-7786.MCR-17-0196. Epub 2017 Jun 7.

46.

Known unknowns and unknown unknowns in suicide risk assessment: evidence from meta-analyses of aleatory and epistemic uncertainty.

Large M, Galletly C, Myles N, Ryan CJ, Myles H.

BJPsych Bull. 2017 Jun;41(3):160-163. doi: 10.1192/pb.bp.116.054940. Review.

47.

Suicide Rates After Discharge From Psychiatric Facilities: A Systematic Review and Meta-analysis.

Chung DT, Ryan CJ, Hadzi-Pavlovic D, Singh SP, Stanton C, Large MM.

JAMA Psychiatry. 2017 Jul 1;74(7):694-702. doi: 10.1001/jamapsychiatry.2017.1044. Review.

48.

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.

Crawford ED, Shore ND, Petrylak DP, Higano CS, Ryan CJ.

Ther Adv Med Oncol. 2017 May;9(5):319-333. doi: 10.1177/1758834017698644. Epub 2017 Mar 22. Review.

49.

Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.

Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR.

J Nucl Med. 2017 Dec;58(12):1956-1961. doi: 10.2967/jnumed.117.192476. Epub 2017 May 18.

50.

In-patient suicide: selection of people at risk, failure of protection and the possibility of causation.

Large MM, Chung DT, Davidson M, Weiser M, Ryan CJ.

BJPsych Open. 2017 May 1;3(3):102-105. doi: 10.1192/bjpo.bp.116.004309. eCollection 2017 May.

Supplemental Content

Support Center